Related by context. All words. (Click for frequent words.) 65 KRAS mutation 64 ZACTIMA 64 thalidomide Thalomid 64 papillary renal cell carcinoma 64 K ras mutations 64 Squamous 64 Tesmilifene 63 INSPIRE Trial Phase III 63 gefitinib Iressa 63 histological subtype 62 sorafenib Nexavar 62 trastuzumab Herceptin ® 62 promoter hypermethylation 62 immunohistochemical analysis 62 Cardiotoxicity 62 metastatic malignant 62 Estrogen Receptor 62 ductal carcinomas 61 T1c 61 polycythemia vera PV 61 MAGE A3 ASCI 61 biliary tract cancer 61 gastrointestinal stromal tumors GISTs 61 Bayer HealthCare Onyx Pharmaceuticals 61 KRAS mutations 61 metastatic pancreatic 61 Carotid Revascularization Endarterectomy vs. 61 Celecoxib APC trial 61 squamous cell lung cancer 61 Velcade bortezomib 61 invasive lobular 61 completely resected 61 CYT# potent vascular disrupting 61 beta carotene supplementation 61 lymphoid malignancies 61 Tumor Response 61 #:#-# [033] 61 erlotinib Tarceva ® 61 prospective multicentre 61 myelofibrosis polycythemia vera 60 Leukemias 60 kidney urologic 60 LHRH receptor positive 60 mutated K ras 60 BRCA1 BRCA2 60 prostate cancer CaP 60 recurrent glioblastoma multiforme 60 ovarian pancreatic 60 pancreatic adenocarcinoma 60 c KIT 60 Pemetrexed 60 selenium supplementation 60 HER2 positive metastatic breast 60 ToGA 60 clinicopathologic 60 CALGB 60 mucinous 60 Histopathological 60 interferon gamma 1b 60 Immunotherapeutic 60 PI3K Akt 60 BCIRG 60 Cancer Incidence Mortality 59 tumor subtypes 59 cancer mCRC 59 transthyretin amyloidosis 59 BEXXAR Therapeutic Regimen 59 EGFR HER2 59 LungAlert TM 59 Lancet Oncology journal 59 neoadjuvant treatment 59 BRAF mutated 59 AVOREN 59 ovarian endometrial 59 Digital Mammographic Imaging 59 brivanib 59 Shark cartilage 59 AACR IASLC Joint 59 NSCLC tumors 59 transrectal ultrasound guided 59 ErbB2 positive 59 Cloretazine 59 tumor histology 59 antiangiogenic agent 59 Folfox 59 Menopausal hormone therapy 59 Papillary 59 Renal Cell Carcinoma RCC 59 recurrent metastatic 59 relapsed ALL 59 Pharmacokinetics PK 59 genotypic resistance 59 Fibroblast 59 deCODE ProstateCancer TM 59 advanced hepatocellular carcinoma 59 clinicopathological 59 epithelial tumors 59 vinca alkaloid 59 #F FDG PET 59 myeloproliferative disorders 59 ASCUS 59 Screening Trial DMIST 59 Squamous Cell 59 Chronic lymphocytic leukemia 59 BRIM3 59 Epidermal Growth Factor Receptor 59 Prevalence Worldwide 58 Multivariate logistic regression 58 immunohistochemical 58 number NCT# ClinicalTrials.gov 58 relapsed MM 58 Cathepsin B 58 colorectal adenocarcinoma 58 flavopiridol 58 HDAC Inhibitor 58 refractory metastatic 58 ALK inhibitors 58 vincristine doxorubicin 58 susceptibility loci 58 HER2 overexpression 58 prostate ovarian 58 essential thrombocythemia ET 58 p# biomarker 58 Trandolapril 58 Kahalalide F 58 prostate carcinoma 58 KRAS status 58 nodal metastasis 58 Adjuvant chemotherapy 58 invasive carcinomas 58 ABCB1 58 demonstrated antitumor activity 58 hematopoietic cancers 58 clinico pathological 58 gastrointestinal stromal tumors GIST 58 myeloproliferative diseases 58 Basal Cell 58 metaplasia 58 metastatic GIST 58 endometriosis ovarian cysts 58 Monoclonal antibody 58 Epigenomics proprietary 58 comparative genomic hybridization 58 Randomized trials 58 malignant polyps 58 TRAIL induced apoptosis 58 Enzastaurin 58 murine models 58 Molecular Cancer 58 trastuzumab DM1 T DM1 58 Histological 58 Chronic Lymphocytic Leukemia CLL 58 variant rs# 58 methylation markers 58 EGFR tyrosine kinase inhibitors 58 MVA MUC1 IL2 58 HER2 amplified 58 histologies 58 deCODE AF TM 58 extramedullary 58 TOP2A 58 chemotherapy hormonal therapy 58 Afatinib 58 ductal adenocarcinoma 58 stage IIIb IV 58 Patient Registry 58 Trastuzumab DM1 58 multivariate analyzes 58 urothelial carcinoma 58 Diabetic Foot Ulcer 58 HER2 expression 58 Epidemiologic studies 58 cerebral microbleeds 58 promoter methylation 58 EGFR mutation positive 57 Hepatocellular Carcinoma HCC 57 LAB CGRP 57 differential gene expression 57 molecular biomarkers 57 #-# Full Text 57 Epivir HBV 57 tramiprosate Alzhemed TM 57 anastrazole 57 CIN2 + 57 preclinical efficacy 57 Cytotoxic T 57 hypermethylated 57 irinotecan oxaliplatin 57 #rd Annual CTRC 57 gene rearrangements 57 pT2 57 Hedgehog Pathway Inhibitor 57 blinded randomized placebo controlled 57 molecular subtypes 57 Neuvenge 57 PSMA ADC 57 Subgroup analysis 57 Nonalcoholic fatty liver 57 observational cohort study 57 Hormone Receptor Positive 57 malignant pleural mesothelioma 57 dasatinib Sprycel ® 57 transcranial Doppler ultrasound 57 tubulin inhibitor 57 SWOG 57 p# mutations 57 biologic pathways 57 ABL1 57 basal cell carcinoma BCC 57 mTOR inhibitors 57 tamoxifen Nolvadex ® 57 Cytogenetic 57 pancreas esophagus 57 Oncotype DX Recurrence Score 57 cardiac repolarization 57 MCSP respectively 57 tumor subtype 57 gastrointestinal stromal 57 Pharmacokinetic PK 57 Gynecologic Oncology Group 57 Histologic 57 UroVysion 57 breast cancer subtypes 57 GPC5 57 DNA methylation biomarker 57 Prostate Lung Colorectal 57 Prednisone Against Refractory 57 vitespen 57 Surgical resection 57 histologic subtype 57 huN# DM1 57 circulating endothelial cells 57 ThermoDox ® clinical 57 LungSign TM 57 PROLARIS 57 neoplasias 57 Xelox 57 NCCN guidelines 57 histological subtypes 57 ADVEXIN therapy 57 TMPRSS2 ERG 57 Stenting Trial CREST 57 Adenomas 57 sarcomatoid 57 LRP5 57 IL# PE#QQR 57 ACOSOG Z# 57 NSABP 57 Aplidin 57 depsipeptide 57 pelvic malignancies 57 TCF#L# gene 57 somatic mutations 57 Prostate AdenoCarcinoma Treatment 57 lymphoproliferative disorders 57 Peptide YY 57 pharmacodynamic markers 57 advanced adenomas 57 Myelodysplastic syndromes MDS 57 nonmelanoma skin cancers 57 Tyrosine Kinase Inhibitors 57 HER2 HER3 57 PARP inhibition 57 Tumor Microenvironment 57 histologic findings 57 Common Toxicity Criteria 57 membranous nephritis 57 cancer.gov 57 NF kB pathway 57 CYP#A# CYP#D# 57 Prostate Px + 57 CCR5 receptor antagonist 57 Oncotype 57 trastuzumab Herceptin 57 Screening Trial 57 receptor tyrosine kinase inhibitor 57 humanised antibody 57 Subtypes 57 miRview TM mets 57 VeriStrat 56 acadesine 56 Hematologic 56 adjuvant radiotherapy 56 BEZ# 56 evaluating Actimmune 56 phase IIIb 56 PCI ExTRACT TIMI 56 urothelial cancer 56 germline mutations 56 NMIBC 56 Dr. Montori 56 neratinib 56 randomized multicenter trial 56 Preclinical Study 56 myelodysplastic myeloproliferative diseases 56 triciribine phosphate monohydrate 56 recurrent NSCLC 56 Hepatotoxicity 56 Septin9 56 Immunohistochemical 56 MGd 56 enzastaurin 56 Sudhir Agrawal D.Phil 56 Trichomonas vaginalis 56 molecular abnormalities 56 preoperative chemotherapy 56 multivariate Cox 56 colorectal carcinoma 56 pertuzumab 56 Sipuleucel T 56 Systemic Sclerosis 56 histopathologic diagnosis 56 sunitinib Sutent 56 Serious Adverse Events 56 OvaRex MAb 56 ERK signaling 56 T#I [002] 56 cytogenic 56 NMP# 56 neuroregenerative 56 Degarelix 56 Onconase 56 FDG PET imaging 56 gastric adenocarcinoma 56 TORISEL TM 56 refractory chronic lymphocytic 56 metastatic neuroendocrine tumors 56 gastric cardia 56 Darapladib 56 Medullary thyroid cancer 56 MGUS 56 prospective nonrandomized 56 Multiple logistic regression 56 hepatic lesions 56 -#.# log# copies mL 56 eosinophilic pneumonia 56 squamous 56 rs# [004] 56 CaPSURE 56 colonoscopy flexible sigmoidoscopy 56 fosbretabulin 56 FDG-PET/CT 56 prospective observational studies 56 cytoreductive nephrectomy 56 lymphomas leukemias 56 Fecal occult blood 56 #p# [003] 56 hamartomas 56 Stage IIIb 56 novel VDA molecule 56 chemoprevention trials 56 CALGB # [002] 56 CIMZIA TM certolizumab pegol 56 logistic regression analyzes 56 oesophageal adenocarcinoma 56 WHEL 56 Wactawski Wende 56 vaginal lesions 56 adriamycin 56 node metastases 56 Myelofibrosis 56 prospective observational cohort 56 fallopian tube cancers 56 AIR CF1 56 fluoropyrimidine 56 Intervention Trial GAIT 56 ixabepilone 56 hypereosinophilic syndrome 56 Accelerated Partial Breast Irradiation 56 CARE HF 56 CTAP# Capsules 56 Antifungals 56 underwent surgical resection 56 Naive Patients 56 colorectal neoplasms 56 Chemotherapeutic Agents 56 CLARITY TIMI 56 AVN# Phase 56 immunohistochemical staining 56 transthyretin TTR mediated amyloidosis 56 Arch Surg 56 PTPN# 56 decompensated liver disease 56 preclinically 56 genetic polymorphisms 56 #:#-#,# CrossRef Medline [002] 56 multivariable analysis 56 asymptomatic metastatic 56 CAMMS# 56 Nicotine Vaccine 56 chronic eosinophilic leukemia 56 STRIDE PD 56 mediated inhibition 56 Lymphocytic 56 CYP#C# [002] 56 YONDELIS R 56 LUX Lung 56 Outpatient Setting 56 Pooled Analysis 56 prospectively randomized 56 PrevOnco 56 FGFR2 56 microdeletions 56 Haptoglobin 56 alkylating 56 Arul M. 56 Oral Fingolimod 56 Hurthle cell 56 radioimmunotherapy RIT 56 Allogeneic 56 BRCA deficient 56 pretransplant 56 mutational status 56 DNAwithPap TM Test 55 Phylogenetic analyzes 55 #:#-# [035] 55 histologic subtypes 55 adenomatous polyps 55 PANVAC VF 55 differentially expressed genes 55 CHARISMA trial 55 operable breast cancer 55 Genetic Variation 55 undergone radical prostatectomy 55 KRAS oncogene 55 Diffuse Large B 55 tipranavir ritonavir 55 midstage clinical 55 prognostic markers 55 Lp PLA 2 55 hormone receptor status 55 molecular biomarker 55 Polymorphisms 55 familial clustering 55 SSc 55 OncotypeDX 55 ExTRACT TIMI 55 Zolinza 55 cMET 55 genetic syndromes 55 undergoing radical cystectomy 55 longitudinal observational study 55 Pertuzumab 55 Lymphoid 55 riociguat 55 Li Fraumeni 55 prokinetic agent 55 underwent resection 55 Velculescu 55 Clinical Antipsychotic Trials 55 Anti Tumor 55 randomized metastatic breast 55 Vizilite 55 bevacizumab Avastin ® 55 diagnostic biomarker 55 subgroup analyzes 55 imatinib resistance 55 RE LY trial 55 Comorbidities 55 dysglycemia 55 Hodgkin lymphoma HL 55 histone deacetylase inhibitor 55 genomic alterations 55 GSTP1 55 Diabetic Neuropathy 55 SABCS 55 Neurobiological 55 phase IIb study 55 multicenter randomized controlled 55 familial pancreatic cancer 55 stage IIIA 55 gene locus 55 aMCI precursor 55 hormone receptor negative 55 Pharmacodynamic 55 drotrecogin alfa activated 55 Asthma Intervention 55 miRview ™ mets 55 SEER registry 55 pain palliation 55 fusion enhancers 55 pharmacogenetic test 55 Colon polyps 55 antiangiogenic agents 55 TGFBR1 * 6A 55 Drug Shows Promise 55 exemestane Aromasin 55 HIV HCV coinfected 55 mutated p# 55 pretreatment serum 55 Trastuzumab Herceptin 55 Neovastat 55 thrombophilia 55 biochemical relapse 55 BRAF V#E mutation 55 CINQUIL 55 meta regression 55 preoperative staging 55 beta1 integrin 55 Genetic variants 55 Experimental Therapeutics Program 55 mycosis fungoides 55 evaluating mipomersen 55 Non Alcoholic Steatohepatitis 55 busulfan 55 orally administered inhibitor 55 GISSI 55 bronchoalveolar lavage fluid 55 neuropsychiatric diseases 55 Rosetta Genomics microRNA 55 Kantarjian 55 SNP rs# [002] 55 Phase #b/#a clinical 55 Myocardial Perfusion Imaging 55 LT NS# 55 Intervention Effectiveness CATIE 55 REVIVE Diabetes 55 bone scintigraphy 55 biologic DMARD 55 Combination REOLYSIN R 55 neuropathologic 55 Phase Ib II 55 evaluating tivozanib 55 Shows Promise Against 55 HepDirect prodrug 55 pathogenetic mechanisms 55 ug dose 55 biliary stones 55 Dana-Farber/Children s Hospital 55 HGPIN 55 fetal chromosomal 55 GELA 55 PARP inhibitor 55 #:#-#,# CrossRef Medline [001] 55 synovial tissue 55 Vidaza azacitidine 55 narcolepsy cataplexy 55 achieved CCyR 55 prostate carcinogenesis 55 selective modulator 55 Sezary syndrome 55 Assay Kits 55 colorectal adenoma 55 Pre RELAX AHF 55 PCa 55 transgenic mouse models 55 NOMID 55 Her2 gene 55 Interferon beta 55 intestinal permeability 55 UGT#A# 55 predictive biomarkers 55 bile acid metabolism 55 NCIC CTG 55 colorectal cancer CRC 55 Sentinel Lymph Node Biopsy 55 chronic myeloid 55 Severe Sepsis 55 PhG alpha 1 55 CDK inhibitor 55 AVADO 55 molecular determinants 55 DNA intercalator 55 synaptogenesis 55 Secondary efficacy endpoints 55 Carotid Endarterectomy 55 Glufosfamide 55 journal Gynecologic Oncology 55 virus HBV 55 ALK mutations 55 AVERROES 55 Oncotype DX colon cancer 55 NuroPro PD 55 prognostic indicators 55 Gleevec imatinib mesylate 55 BladderChek 55 BMC Musculoskeletal Disorders 55 CTRC AACR San Antonio 55 leiomyomas 55 essential thrombocythemia 55 Virulizin ® 55 multicentric 55 advanced adenoma 55 Fas ligand 55 PC# cells 55 ß blockers 55 efalizumab 55 Subgroup analyzes 54 BLP# Liposome Vaccine 54 Subsets 54 Kaplan Meier analysis 54 ANN INTERN MED 54 thoracoscopic lobectomy 54 histopathological 54 chemosensitivity 54 Oncotype DX ® 54 impaired glucose metabolism 54 Molecular Psychiatry 54 Sjögren syndrome 54 physiologic mechanisms 54 BREVAGen ™ 54 GRNVAC1 54 oral squamous cell 54 Lymph node 54 vascular endothelial dysfunction 54 etiologic 54 E. faecalis 54 Erlotinib 54 dysplastic lesions caused 54 Sentinel node biopsy 54 Xanafide 54 retrospective cohort 54 discontinued Viread 54 including eniluracil ADH 54 pharmacodynamic properties 54 #q# deletion 54 hepatocellular carcinomas 54 pathogenic mechanisms 54 malignant ascites 54 Endometrial cancer 54 underlying vasculopathy 54 CLL SLL 54 Accessed #/#/# [001] 54 By JENNIFER LEARN 54 haematologic 54 dietary acrylamide 54 prednisone prednisolone plus 54 Arimidex anastrozole 54 Relapsing remitting MS 54 Mg Usa 54 bronchioloalveolar carcinoma 54 testicular germ cell 54 genomewide association study 54 MammaPrint R 54 activating mutation 54 gadobutrol 54 Roche AmpliChip 54 Septin 9 54 Relapsing remitting 54 Randomized controlled 54 Angiotensin converting enzyme 54 Pharmacologic 54 Clinical Outcome 54 prenatal exposures 54 metaanalysis 54 HBeAg negative 54 GERD migraine headaches 54 ergot alkaloids 54 Cancer Epidemiol Biomarkers Prev 54 COL#A# 54 reslizumab 54 Clusterin 54 bronchial epithelial cells 54 K RAS 54 Squalamine 54 FOLOTYN ® 54 miRview meso 54 microsatellite instability 54 miRview ™ squamous 54 deCODE BreastCancer 54 Galectin 3 54 QRT PCR 54 splice variant 54 Microalbuminuria 54 Proellex TM 54 NuroPro R 54 anti angiogenic therapy 54 Febit 54 bazedoxifene conjugated estrogens 54 axitinib 54 Gastrointestinal Oncology 54 Brodmann Area 54 www.cancer.gov 54 PORxin TM platforms 54 sleeve lobectomy 54 Vascugel ® 54 SPRYCEL ® 54 GRP# 54 melanocortin receptor 54 TTR amyloidosis 54 recurrent glioma 54 Colorectal Cancers 54 Chronic HCV 54 antisense inhibitor 54 IPAH 54 immunochemical 54 Human Leukocyte Antigen 54 Exelixis XL# 54 Epstein Barr Virus EBV 54 esophagus bladder 54 Triapine 54 renoprotective 54 prostate adenocarcinoma 54 prostate cancer PCa 54 PF # [002] 54 targeting miR 54 non nucleoside HCV 54 miRNA expression 54 Poordad 54 Neuroepidemiology 54 CytoSure 54 distant metastasis 54 V#F mutation 54 multiple logistic regression 54 chromium supplementation 54 extracolonic findings 54 gp# protein [002] 54 constipation OIC 54 pituitary adenomas 54 microRNA profiling 54 drug GAP #B# 54 univariate analyzes 54 TIMP 1 54 benign prostatic hypertrophy BPH 54 PLX STROKE targeting 54 monoinfected patients 54 #th Interscience Conference 54 JAK2 enzyme 54 Non Alcoholic Fatty 54 Chronic Renal Failure 54 receptor subtypes 54 Cloretazine VNP#M 54 alpha#beta# 54 IDH mutations 54 NEUVENGE 54 VerifyNow P#Y# 54 Targretin capsules 54 HCV NS5B polymerase 54 Dr. Ayalew Tefferi 54 CYP #D# 54 eribulin mesylate 54 Cholesterol Levels SPARCL 54 FLT3 54 psoriasis Crohn disease 54 fecal immunochemical test 54 Single Nucleotide Polymorphisms SNPs 54 proton MR spectroscopy 54 LSRO 54 apoptotic pathway 54 Progressive Multifocal Leukoencephalopathy 54 cytological 54 HBV genotypes 54 Septic Shock 54 Controlled Trial 54 cyclophosphamide methotrexate 54 Hp2 2 54 synthetic progestin 54 HLA A2 54 Patients Receiving 54 serum leptin 54 Inhibitory 54 differentiate squamous 54 gondii 54 pharmacodynamic parameters 54 spiral computed tomography 54 GPx 54 follicular lymphoma FL 54 selective inhibition 54 prognostic significance 54 Candida infection 54 simplex virus 54 Cervista HPV HR 54 BSGI MBI 54 CT Colonography 54 erythropoietic 54 Tarvacin 54 cell adhesion molecule 54 faecal occult blood 54 Tigecycline 54 myelofibrosis MF 54 mechanistic insights 54 WHIMS 54 Human papillomavirus 54 gene polymorphism 54 Antitumor Activity 54 SEER database 54 inactivating mutations 54 PREVENT IV 54 MGMT gene 54 Univariate analysis 54 localized prostate 54 TP# mutations 54 anthracycline containing 54 pelvic ultrasound 54 adjuvant therapies 54 novel emulsion formulation 54 Treatment Shows Promise 54 Lewy bodies DLB 54 Patricia Hartge 54 rhinovirus infections 54 polycythemia vera essential thrombocythemia 54 BPS IC 54 BARI 2D 54 lorvotuzumab mertansine 54 abnormal p# 54 TÎ ² 4 54 seropositivity 54 anterior pituitary 54 genes differentially expressed 54 OMP #M# 54 Entamoeba histolytica 54 Chemoprevention 54 tumorigenicity 54 vivo preclinical 54 metastatic RCC 54 thymoma 54 DCVax R 54 Alequel 54 chromosome #p#.# 53 tigecycline 53 aberrant methylation 53 intra abdominal abscess 53 prognostic variables 53 Cardiomyocytes 53 ICON7 53 Combo Therapy 53 ZNF# 53 hepatic metastases 53 Inflammatory Markers 53 farletuzumab 53 Serological 53 YONDELIS 53 ISTODAX ® 53 GRNCM1 53 upper aerodigestive tract 53 Intervention Effectiveness 53 malignant lymphomas 53 RECORD1 53 Analytical Method 53 Glucosamine Chondroitin Arthritis 53 HCV SPRINT 53 HLA DQ 53 irinotecan cisplatin 53 ASCO GI 53 Adverse Event 53 β blockers 53 Prostatitis 53 motor neuron degeneration 53 antiphospholipid antibodies 53 Clinical Infectious Disease 53 follicular adenoma 53 collagenous colitis 53 Bafetinib 53 Cardiolite ® 53 tissue microarrays 53 hepatic cirrhosis 53 Onychomycosis 53 HBeAg 53 ADMIRE HF 53 breast cancer metastasis 53 cellular immunotherapy 53 seminomas 53 Chicago Multidisciplinary Symposium 53 silent myocardial ischemia 53 pharmacogenetic testing 53 histone deacetylase HDAC inhibitor 53 proliferative disorders 53 ImmuKnow R 53 percutaneous biopsy 53 surgically resected 53 ChronVac C ® 53 RE LY 53 cutaneous melanoma 53 pharmacologic treatments 53 Chlamydia psittaci 53 Wisconsin Sleep Cohort 53 BCG refractory 53 thyroglobulin 53 ALN HPN 53 Edge STudy 53 FISH fluorescence 53 mertansine 53 hepatorenal syndrome 53 immunoblotting 53 CHD7 53 protein tyrosine phosphatase 53 glucocorticoid induced osteoporosis 53 Cytomegalovirus CMV 53 leukemia lymphomas 53 EarlyCDT Lung 53 bronchoalveolar lavage 53 multicenter placebo controlled 53 shorter telomere length 53 splice variants 53 vitro assay 53 guideline concordant 53 sCJD 53 Risk Stratification 53 chromosome #p# [002] 53 transvaginal sonography 53 ara C 53 Group RTOG 53 pilocytic astrocytomas 53 immune dysregulation 53 QuadraSphere 53 GG genotype 53 CC genotype 53 Respiratory Virus 53 multivariate logistic regression 53 Lenalidomide 53 advanced metastatic prostate 53 thrombocytopenic 53 MenACWY 53 proteasome inhibitor 53 tropism testing 53 susceptibility locus 53 Protelos R 53 Inflammatory bowel disease 53 Her2/neu 53 multivariate regression analysis 53 Gleevec resistant 53 CATIE AD 53 Genotypes 53 DMSc 53 pharyngeal cancer 53 WDR# 53 EGFR TKIs 53 Randomized Controlled Trials 53 Nilotinib 53 cranial irradiation 53 conditional logistic regression 53 LV dysfunction 53 PROCHYMAL 53 tested eribulin 53 Thymosin Beta 4 53 non coding RNA 53 florbetaben 53 subanalysis 53 thromboembolic disease 53 pregnancy bacterial vaginosis 53 commercialize deforolimus 53 TNM staging 53 FluCAM arm 53 Diabetes Interventions 53 JAK mutations 53 Evoltra ® 53 androgen receptor AR 53 Dr. Victor Velculescu 53 histopathological examination 53 test FOBT 53 Autoimmune Disease 53 GLOBOCAN 53 Aromatase Inhibitors 53 AtherOx 53 MiCK assay 53 oblimersen 53 Modrenal 53 malignant mesothelioma Alfacell 53 ConclusionThis 53 Antisoma AS# 53 PROSTVAC TM 53 HuMax 53 neuroactive 53 clefting 53 basal cell nevus syndrome 53 SNCA 53 Bronchial Thermoplasty 53 Interferon alfa 53 EUS FNA 53 Tor Bjerkedal report 53 glial tumors 53 Diagnostic Criteria 53 TURBT 53 MVax R 53 cytogenetic abnormalities 53 metabolomic profiles 53 acyclovir Lauriad R 53 abnormal cytology 53 hematological parameters 53 myeloproliferative 53 surgically resectable 53 oral JAK1 53 hematopoietic malignancies 53 F FDG PET 53 Univariate 53 familial amyloidotic polyneuropathy FAP 53 electrophysiologic 53 hypersensitivity allergic reactions 53 hERG 53 multicenter Phase II 53 hemangioblast 53 diabetes mellitus DM 53 Pneumocystis carinii pneumonia 53 Dialysis Outcomes 53 sputum specimens 53 NRTI resistance 53 Predisposition 53 plasma pharmacokinetics 53 afatinib 53 arterial calcification 53 enzyme immunoassay EIA 53 pleiotropic effects 53 ECASS 53 monogenic 53 transthoracic 53 Lisofylline 53 INC# 53 genetic loci 53 gastrin analogue TT